Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting

被引：0
|
作者：
Bu, Qiling [1 ]
Zhu, Hong-Hu [1 ,2 ]
Chen, Wenming [1 ]
机构：
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Hematol, 8 Gongtinanlu, Beijing 100020, Peoples R China
[2] Chinese Inst Med Res, Beijing 100005, Peoples R China
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2025年 / 18卷 / 01期
关键词：
Immunoglobulin light chain amyloidosis; Targeted therapies; Clinical trials;
D O I：
10.1186/s13045-025-01681-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunoglobulin light chain (AL) amyloidosis is an incurable disease caused by the accumulation and sedimentation of unstable free light chains produced by monoclonal plasma cells. The key to treatment is to achieve a deep hematologic remission in order to improve organ function or reverse organ dysfunction. Conventional treatment has not been able to fully meet the treatment needs of patients with AL, while therapies targeting malignant plasma cells or amyloid have potentially improved treatment outcomes. This study provides an overview of the latest reports on targeted therapies for AL amyloidosis from the 2024 ASH Annual Meeting.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] AMYLOID LIGHT-CHAIN AMYLOIDOSIS: ESTABLISHED AND NOVEL THERAPIES
    Palladini, G.
    Basset, M.
    HAEMATOLOGICA, 2018, 103 : 7 - 7
  • [42] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
    Xubo Gong
    Yi Zhang
    Xin He
    Milad Moloudizargari
    Teng Yu
    Lin Wang
    Weiwei Liu
    Lan Jin
    Huiying Xu
    Yang Xu
    Zhihua Tao
    Wenbin Qian
    Experimental Hematology & Oncology, 12
  • [43] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
    Gong, Xubo
    Zhang, Yi
    He, Xin
    Moloudizargari, Milad
    Yu, Teng
    Wang, Lin
    Liu, Weiwei
    Jin, Lan
    Xu, Huiying
    Xu, Yang
    Tao, Zhihua
    Qian, Wenbin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [44] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
    Xubo Gong
    Xin He
    Lin Wang
    Teng Yu
    Weiwei Liu
    Huiying Xu
    Lan Jin
    Xiang Li
    Bin Zhang
    Zhihua Tao
    Wenbin Qian
    Experimental Hematology & Oncology, 13
  • [45] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
    Gong, Xubo
    He, Xin
    Wang, Lin
    Yu, Teng
    Liu, Weiwei
    Xu, Huiying
    Jin, Lan
    Li, Xiang
    Zhang, Bin
    Tao, Zhihua
    Qian, Wenbin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [46] Cardiovascular toxicity from therapies for light chain amyloidosis
    Morfino, Paolo
    Aimo, Alberto
    Castiglione, Vincenzo
    Chianca, Michela
    Vergaro, Giuseppe
    Cipolla, Carlo Maria
    Fedele, Antonella
    Emdin, Michele
    Fabiani, Iacopo
    Cardinale, Daniela
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [47] Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024
    Gong, Xubo
    Zhang, Lianjun
    He, Xin
    Yang, Jing
    Li, Xiang
    Liu, Weiwei
    Zhang, Bin
    Tao, Zhihua
    Qian, Wenbin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [48] Immunotherapy for head and neck tumors: Updates from the 2024 ASCO Annual Meeting
    von Witzleben, Adrian
    Doescher, Johannes
    Hoffmann, Thomas K.
    Laban, Simon
    HNO, 2024, 72 (12) : 850 - 856
  • [49] Highlights from the 66th ASH Annual Meeting 2024
    Schmale, Ine
    ACTA HAEMATOLOGICA, 2025, 148 (02)
  • [50] Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
    Xia, Jieyun
    Li, Zhenyu
    Xu, Kailin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
12345